Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19

Article  CAS  PubMed  Google Scholar 

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, Trial HRF (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809

Article  CAS  PubMed  Google Scholar 

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Trial HPF (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822

Article  CAS  PubMed  Google Scholar 

Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101

CAS  PubMed  Google Scholar 

Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159–178

Article  CAS  PubMed  Google Scholar 

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593

Article  CAS  PubMed  Google Scholar 

Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB, Holen I (2021) Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev 101(3):797–855

Article  CAS  PubMed  Google Scholar 

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline update. J Clin Oncol 35(35):3978–3986

Article  CAS  PubMed  Google Scholar 

Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321

Article  CAS  PubMed  Google Scholar 

Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21(16):3150–3157

Article  CAS  PubMed  Google Scholar 

Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100(12):2613–2621

Article  CAS  PubMed  Google Scholar 

Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49(1):20–33

Article  CAS  PubMed  Google Scholar 

Russell RG (2006) Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 1068:367–401

Article  ADS  CAS  PubMed  Google Scholar 

Flanagan AM, Chambers TJ (1991) Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49(6):407–415

Article  CAS  PubMed  Google Scholar 

Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10(10):1478–1487

Article  CAS  PubMed  Google Scholar 

Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK (1996) Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50(5):1127–1138

CAS  PubMed  Google Scholar 

Coxon FP, Helfrich MH, Van’t Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15(8):1467–76

Article  CAS  PubMed  Google Scholar 

Holmberg AR, Lerner UH, Alayia AA, Al-Mohanna M, Adra C, Marquez M, Meurling L, Nilsson S (2010) Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis. Int J Oncol 37(3):563–567

Article  CAS  PubMed  Google Scholar 

Lerner UH (1987) Modifications of the mouse calvarial technique improve the responsiveness to stimulators of bone resorption. J Bone Miner Res 2(5):375–383

Article  CAS  PubMed  Google Scholar 

Ljunggren O, Ransjo M, Lerner UH (1991) In vitro studies on bone resorption in neonatal mouse calvariae using a modified dissection technique giving four samples of bone from each calvaria. J Bone Miner Res 6(6):543–550

Article  CAS  PubMed  Google Scholar 

Granholm S, Henning P, Lindholm C, Lerner UH (2013) Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2. Bone 52(1):83–92

Article  CAS  PubMed  Google Scholar 

Ayturk UM, Scollan JP, Goz Ayturk D, Suh ES, Vesprey A, Jacobsen CM, Divieti Pajevic P, Warman ML (2020) Single-cell RNA sequencing of calvarial and long-bone endocortical cells. J Bone Miner Res 35(10):1981–1991

Article  CAS  PubMed  Google Scholar 

Takeshita S, Kaji K, Kudo A (2000) Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15(8):1477–1488

Article  CAS  PubMed  Google Scholar 

Zenger S, Hollberg K, Ljusberg J, Norgard M, Ek-Rylander B, Kiviranta R, Andersson G (2007) Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone 41(5):820–832

Article  CAS  PubMed  Google Scholar 

Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 281(5):2414–2429

Article  CAS  PubMed  Google Scholar 

Conaway HH, Henning P, Lerner UH (2013) Vitamin a metabolism, action, and role in skeletal homeostasis. Endocr Rev 34(6):766–797

Article  CAS  PubMed  Google Scholar 

Conaway HH, Pirhayati A, Persson E, Pettersson U, Svensson O, Lindholm C, Henning P, Tuckermann J, Lerner UH (2011) Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. J Biol Chem 286(36):31425–31436

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG (2019) Pharmacology of bisphosphonates. Br J Clin Pharmacol 85(6):1052–1062

Article  PubMed  PubMed Central  Google Scholar 

Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T (1988) Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122(4):1373–1382

Article  CAS  PubMed  Google Scholar 

Thellenberg-Karlsson C, Nyman C, Nilsson S, Blom R, Marquez M, Castellanos E, Holmberg AR (2016) Bone-targeted novel cytotoxic polybisphosphonate conjugate in castration-resistant prostate cancer: a multicenter phase 1 study. Anticancer Res 36(12):6499–6504

Article  CAS  PubMed  Google Scholar 

Thellenberg-Karlsson C, Vjaters E, Kase M, Tammela T, Ojamaa K, Norming U, Nyman C, Andersson SO, Hublarovs O, Marquez-Holmberg M, Castellanos E, Ullen A, Holmberg A, Nilsson S (2023) A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases. Eur J Cancer 181:198–207

Article  CAS  PubMed  Google Scholar 

Martin TJ, Sims NA (2015) RANKL/OPG; Critical role in bone physiology. Rev Endocr Metab Disord 16(2):131–139

Article  CAS  PubMed  Google Scholar 

Granholm S, Lundberg P, Lerner UH (2007) Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-B and c-Fms. J Endocrinol 195(3):415–427

Article  CAS  PubMed  Google Scholar 

Tsukasaki M, Takayanagi H (2019) Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol 19(10):626–642

Article